5‐aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis

Although 5‐aminosalicylate (5‐ASA) is the therapy of first choice in ulcerative colitis (UC), some patients cannot tolerate it because of side effects. Previous reports have not investigated whether 5‐ASA intolerance is associated with the risk of colectomy.

[1]  M. Hattori,et al.  5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis , 2020, Intestinal research.

[2]  Jun Kato,et al.  Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents , 2019, Journal of clinical medicine.

[3]  Wei Yan,et al.  The culprit of mesalamine intolerance: case series and literature review , 2019, BMC Gastroenterology.

[4]  C. Sokollik,et al.  Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study , 2018, Journal of Crohn's & colitis.

[5]  G. Kaplan,et al.  Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study , 2017, Inflammatory bowel diseases.

[6]  Siddharth Singh,et al.  Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  S. Ng,et al.  Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry. , 2016, Journal of Crohn's & colitis.

[8]  A. Majeed,et al.  The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population‐based study of incident cases between 1989–2009 , 2015, Alimentary pharmacology & therapeutics.

[9]  S. Ishihara,et al.  Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration , 2014, BioMed research international.

[10]  B. Feagan,et al.  Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews , 2013, Inflammatory bowel diseases.

[11]  F. Daniel,et al.  Isolated fever induced by mesalamine treatment. , 2013, World journal of gastroenterology.

[12]  G. D'Haens,et al.  Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[13]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[14]  T. Hibi,et al.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: A double-blind, randomized study , 2010, Inflammatory bowel diseases.

[15]  M. Campieri,et al.  Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.

[16]  D. Jewell,et al.  Long‐term outcome after admission for acute severe ulcerative colitis in Oxford: The 1992–1993 cohort , 2009, Inflammatory bowel diseases.

[17]  M. Vatn,et al.  Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. , 2007, Gastroenterology.

[18]  P. Desreumaux,et al.  Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence , 2006, Alimentary pharmacology & therapeutics.

[19]  S. Hanauer,et al.  Comparative Analysis of the in Vitro Prosecretory Effects of Balsalazide, Sulfasalazine, Olsalazine, and Mesalamine in Rabbit Distal Ileum , 2005, Inflammatory bowel diseases.

[20]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[21]  P. Mergo,et al.  Mesalamine-Related Lung Disease: Clinical, Radiographic, and Pathologic Manifestations , 2003, Inflammatory bowel diseases.

[22]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[23]  G. Spera,et al.  Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  M. Gonzalo,et al.  Desensitization after fever induced by mesalazine , 1999, Allergy.

[25]  D. Milov,et al.  Massive pericardial effusion in a child following the administration of mesalamine. , 1997, Journal of pediatric gastroenterology and nutrition.

[26]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[27]  G. Williams,et al.  Mesalazine induced exacerbation of ulcerative colitis. , 1995, Gut.

[28]  P. Miner,et al.  Exacerbation of chronic ulcerative colitis with mesalamine. , 1995, Gastroenterology.

[29]  K. Hine,et al.  Drug points: Fever, vasculitic rash, arthritis, pericarditis, and pericardial effusion after mesalazine , 1994, BMJ.

[30]  C. Holdsworth,et al.  Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine , 1992, Alimentary pharmacology & therapeutics.

[31]  R. Heading,et al.  Salicylate induced exacerbation of ulcerative colitis. , 1987, Gut.

[32]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[33]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[34]  E. Ben-Chetrit,et al.  Mesalamine-induced hypersensitivity pneumonitis. A case report and review of the literature. , 1997, Journal of clinical gastroenterology.